Bayer receives FDA approval for long-term contraceptive

Bayer receives FDA approval for long-term contraceptive
Bayer HealthCare has received approval from the U.S. Food and Drug Administration for its new low-dose levonorgestrel-releasing intrauterine system called Skyla, according a Jan. 10 news release issued by the company.

(HealthDay)—Bayer HealthCare has received approval from the U.S. Food and Drug Administration for its new low-dose levonorgestrel-releasing intrauterine system (IUS) called Skyla, according a Jan. 10 news release issued by the company.

Bayer describes Skyla as a small, flexible plastic T-shaped device containing 13.5 mg of the hormone levonorgestrel. The 28 mm × 30 mm Skyla T-body is put in place through a 3.8 mm-diameter tube. A slow, low dose of is locally released in the uterus, with only small amounts of the hormone entering the bloodstream. The IUS prevents pregnancy for up to three years.

The regulatory approval of Skyla was based on data from a multi-national, randomized open-label Phase 3 trial of 2,884 women (aged 18 to 35 years), in which 1,432 women received Skyla. The IUS was 99 percent effective in preventing pregnancy and was well tolerated with no unexpected . There were low incidences of ectopic pregnancy, , expulsion of the device from the uterus, and uterine perforation.

"The approval of Skyla in the United States highlights Bayer's continued commitment to drive innovation and empower women with a variety of birth control options at different reproductive stages of their lives," Kemal Malik, M.D., Bayer's head of global development, said in a statement.

More information: More Information

add to favorites email to friend print save as pdf

Related Stories

ACOG: Intrauterine device insertion linked to weight loss

May 07, 2012

(HealthDay) -- Women who undergo postpartum or interval insertion of Levonorgestrel-releasing Intrauterine System (LNG-IUS) or Copper T 380A (CU-T) intrauterine devices experience weight loss in the two years ...

'Morning After Pill' Works up to 5 Days After Sex

Feb 22, 2010

(PhysOrg.com) -- A team of researchers from the United States and Europe has published new evidence supporting the use of ulipristal acetate as an effective alternative to levonorgestrel (marketed as Plan B®) for emergency ...

FDA ties newer birth control drugs to blood clots

Oct 27, 2011

(AP) -- Safety concerns with the popular birth control pill Yaz increased Thursday as federal health scientists reported that the Bayer drug and other newer birth control treatments appear to increase the risk of dangerous ...

Consider IUDs for contraception, other conditions

Apr 13, 2012

Researchers at the University of Cincinnati (UC) have found that intrauterine devices (IUDs) containing progesterone are a safe and effective means of birth control and support its use as a treatment option for medical conditions ...

Recommended for you

High-dose opioid prescribing continues to climb

Sep 12, 2014

High-dose opioid prescribing increased by 23 per cent in Canada between 2006 and 2011, despite clinical guidelines recommending that most patients should avoid high-doses of these drugs, according to new ...

Feds say Bayer colon supplement makes bogus claims

Sep 12, 2014

The United States government accused Bayer of making scientifically unproven statements about the health benefits of a popular probiotic on Friday, claiming the German pharmaceutical giant was in contempt of court.

FDA approves weight-loss drug Contrave (Update)

Sep 11, 2014

U.S. regulators have greenlighted a new weight-loss drug called Contrave, the third in a string of approvals for prescription medications aimed at the nation's 78 million obese adults.

User comments